Patents by Inventor Michael A. Abrams
Michael A. Abrams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970137Abstract: A vehicle includes a storage compartment, a belt conveyor located in the storage compartment and having a slat belt supported by a pair of rollers, and a shelf operatively coupled to the slat belt and configured to move between a lower stowed position within the storage compartment and an upper deployed position extending outward from the storage compartment.Type: GrantFiled: September 6, 2022Date of Patent: April 30, 2024Assignee: Ford Global Technologies, LLCInventors: Stuart C. Salter, David Brian Glickman, Jeff Robert Seaman, Annette Lynn Huebner, George Abram Thornton, Michael John Harmon
-
Publication number: 20240075883Abstract: A vehicle includes a storage compartment, a belt conveyor located in the storage compartment and having a slat belt supported by a pair of rollers, and a shelf operatively coupled to the slat belt and configured to move between a lower stowed position within the storage compartment and an upper deployed position extending outward from the storage compartment.Type: ApplicationFiled: September 6, 2022Publication date: March 7, 2024Applicant: Ford Global Technologies, LLCInventors: Stuart C. Salter, David Brian Glickman, Jeff Robert Seaman, Annette Lynn Huebner, George Abram Thornton, Michael John Harmon
-
Publication number: 20220366281Abstract: In various embodiments, a character engine models a character that interacts with users The modeling techniques include evaluating user input data that is associated with a user device to identify a user intent and an assessment domain, selecting a first set of inference algorithms from a plurality of inference algorithms based, at least in part, on the user intent and the assessment domain, and applying the user intent and the assessment domain to the first set of inference algorithms to generate a plurality of inferences.Type: ApplicationFiled: July 25, 2022Publication date: November 17, 2022Inventors: Michael ABRAMS, Eric HASELTINE
-
Patent number: 11455549Abstract: In one embodiment, a character engine models a character that interacts with users. The character engine receives user input data from a user device, and analyzes the user input data to determine a user intent and an assessment domain. Subsequently, the character engine selects inference algorithm(s) that include machine learning capabilities based on the intent and the assessment domain. The character engine computes a response to the user input data based on the selected inference algorithm(s) and a set of personality characteristics that are associated with the character. Finally, the character engine causes the user device to output the response to the user. In this fashion, the character engine includes sensing functionality, thinking and learning functionality, and expressing functionality.Type: GrantFiled: December 8, 2016Date of Patent: September 27, 2022Assignee: Disney Enterprises, Inc.Inventors: Michael Abrams, Eric Haseltine
-
Patent number: 11423317Abstract: In one embodiment, a character engine models a character that interacts with users. The character engine receives user input data from a user device, and analyzes the user input data to determine a user intent and an assessment domain. Subsequently, the character engine selects inference algorithm(s) that include machine learning capabilities based on the intent and the assessment domain. The character engine computes a response to the user input data based on the selected inference algorithm(s) and a set of personality characteristics that are associated with the character. Finally, the character engine causes the user device to output the response to the user. In this fashion, the character engine includes sensing functionality, thinking and learning functionality, and expressing functionality.Type: GrantFiled: December 8, 2016Date of Patent: August 23, 2022Assignee: Disney Enterprises, Inc.Inventors: Michael Abrams, Eric Haseltine
-
Patent number: 11311598Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.Type: GrantFiled: April 9, 2019Date of Patent: April 26, 2022Assignee: Soligenix, Inc.Inventors: Oreola Donini, Annett Rozek, Jackson Lee, John North, Michael Abrams
-
Publication number: 20200323946Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.Type: ApplicationFiled: April 9, 2019Publication date: October 15, 2020Inventors: Oreola Donini, Annett Rozek, Jackson Lee, John Carpenter, Michael Abrams
-
Patent number: 10253068Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.Type: GrantFiled: December 20, 2017Date of Patent: April 9, 2019Assignee: Soligenix, Inc.Inventors: Oreola Donini, Annett Rozek, Jackson Lee, John North, Michael Abrams
-
Publication number: 20180170964Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.Type: ApplicationFiled: December 20, 2017Publication date: June 21, 2018Inventors: Oreola Donini, Annett Rozek, Jackson Lee, John North, Michael Abrams
-
Publication number: 20180165596Abstract: In one embodiment, a character engine models a character that interacts with users. The character engine receives user input data from a user device, and analyzes the user input data to determine a user intent and an assessment domain. Subsequently, the character engine selects inference algorithm(s) that include machine learning capabilities based on the intent and the assessment domain. The character engine computes a response to the user input data based on the selected inference algorithm(s) and a set of personality characteristics that are associated with the character. Finally, the character engine causes the user device to output the response to the user. In this fashion, the character engine includes sensing functionality, thinking and learning functionality, and expressing functionality.Type: ApplicationFiled: December 8, 2016Publication date: June 14, 2018Inventors: Michael ABRAMS, Eric HASELTINE
-
Patent number: 9850279Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.Type: GrantFiled: August 11, 2014Date of Patent: December 26, 2017Assignee: Soligenix, Inc.Inventors: Oreola Donini, Annett Rozek, Jackson Lee, John North, Michael Abrams
-
Publication number: 20170175523Abstract: A method for analyzing total oil in place and fraction that is movable oil in a fine gain rock formation includes monitoring thermal extraction of hydrocarbon and non-hydrocarbon compounds from a sample of a subsurface formation by heating the sample. The heating has a selected initial temperature, and a temperature increase at a selected rate to a final temperature. The extracted hydrocarbon and non-hydrocarbon compounds are passed through a capillary column to a flame ionization detector. Types of hydrocarbon and non-hydrocarbon compounds and relative fractional amounts of each type thereof are determined from the sample by analyzing a chemical thermogram generated by the flame ionization detector.Type: ApplicationFiled: March 30, 2015Publication date: June 22, 2017Applicant: APACHE CORPORATIONInventor: Michael A. Abrams
-
Publication number: 20170049474Abstract: A trocar or surgical port assembly includes an annular body attachable to a patient at an incision in a patient. The annular body includes a cylindrical insert portion defining a proximal end and a distal end and a flange disposed at the proximal end of the cylindrical insert portion. A skirt is attached to the distal end of the cylindrical insert portion and extends distally from the annular body and includes a flexible web and a wire attached to the flexible web that in a multiple looped configuration of non-intersecting curved portions positioned in the vicinity of the distal portion of the skirt to enable the flexible web to be biased via a biasing force exerted by the wire into a funnel-shaped open configuration having an opening of the skirt at the distal portion of the skirt that is larger than an opening of the skirt at the proximal portion.Type: ApplicationFiled: September 23, 2016Publication date: February 23, 2017Inventors: Gregory Piskun, Oleg Shikhman, Christopher Battles, Patrick N. Gutelius, Mark J. DeBisschop, Jeffrey H. MacDonald, Frank Rende, Michael Abrams, Anatoly Konik, Dan Rottenberg
-
Patent number: 9492195Abstract: A surgical port comprising a body and first and second cannula extending from the body and movable with respect to the body via an instrument inserted through the respective cannula. The cannulas can extend distally from the body and can include one or more seals. A port assembly and first and second instruments manipulatable in a crossed configuration are also disclosed.Type: GrantFiled: January 19, 2015Date of Patent: November 15, 2016Assignee: Covidien LPInventors: Gregory Piskun, Oleg Shikhman, Christopher Battles, Patrick N. Gutelius, Mark J. DeBisschop, Jeffrey H. MacDonald, Frank Rende, Michael Abrams, Anatoly Konik, Dan Rottenberg
-
Publication number: 20160229890Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.Type: ApplicationFiled: August 11, 2014Publication date: August 11, 2016Inventors: Oreola Donini, Annett Rozek, Jackson Lee, John North, Michael Abrams
-
Patent number: 9314267Abstract: Various embodiments of a laparoscopic trocar assembly are disclosed. The port assemblies include inserted parts that protect the patient's tissues at the point of deployment. The port assemblies include seals for maintaining pneumoperitoneum both when instrument are being used and when instruments are not inserted.Type: GrantFiled: November 21, 2014Date of Patent: April 19, 2016Assignee: Covidien LPInventors: Gregory Piskun, Christopher Battles, Frank Rende, Michael Abrams, Oleg Shikhman
-
Publication number: 20150148613Abstract: A surgical port comprising a body and first and second cannula extending from the body and movable with respect to the body via an instrument inserted through the respective cannula. The cannulas can extend distally from the body and can include one or more seals. A port assembly and first and second instruments manipulatable in a crossed configuration are also disclosed.Type: ApplicationFiled: January 19, 2015Publication date: May 28, 2015Inventors: Gregory Piskun, Oleg Shikhman, Christopher Battles, Patrick N. Gutelius, Mark J. DeBisschop, Jeffrey H. MacDonald, Frank Rende, Michael Abrams, Anatoly Konik, Dan Rottenberg
-
Publication number: 20150080931Abstract: Various embodiments of a laparoscopic trocar assembly are disclosed. The port assemblies include inserted parts that protect the patient's tissues at the point of deployment. The port assemblies include seals for maintaining pneumoperitoneum both when instrument are being used and when instruments are not inserted.Type: ApplicationFiled: November 21, 2014Publication date: March 19, 2015Inventors: Gregory Piskun, Christopher Battles, Frank Rende, Michael Abrams, Oleg Shikhman
-
Patent number: 8961407Abstract: A surgical port comprising a body and first and second cannula extending from the body and movable with respect to the body via an instrument inserted through the respective cannula. The cannulas can extend distally from the body and can include one or more seals. A port assembly and first and second instruments manipulatable in a crossed configuration are also disclosed.Type: GrantFiled: August 31, 2009Date of Patent: February 24, 2015Assignee: Covidien LPInventors: Gregory Piskun, Oleg Shikhman, Christopher Battles, Patrick N. Gutelius, Mark J. DeBisschop, Jeffrey H. MacDonald, Frank Rende, Michael Abrams, Anatoly Konik, Dan Rottenberg
-
Patent number: 8911365Abstract: Various embodiments of a laparoscopic trocar assembly are disclosed. The port assemblies include inserted parts that protect the patient's tissues at the point of deployment. The port assemblies include seals for maintaining pneumoperitoneum both when instrument are being used and when instruments are not inserted.Type: GrantFiled: August 13, 2008Date of Patent: December 16, 2014Assignee: Covidien LPInventors: Gregory Piskun, Christopher Battles, Frank Rende, Michael Abrams, Oleg Shikhman